Mansi H. Patel, Divya M. Jadav, Mitali Dalwadi, Ritika Gajre, Chainesh Shah, U. M. Upadhyay
Mansi H. Patel1*, Divya M. Jadav2, Mitali Dalwadi3, Ritika gajre4, Chainesh shah4, U. M. Upadhyay6
Department of Quality Assurance, Sigma Institute of Pharmacy, At., Post Bakrol, Ta: Waghodia, Dist: Vadodara-390019, Gujarat, India.
Volume - 13,
Issue - 4,
Year - 2021
Impurities in medicine formulation aren't acceptable. It's defined as any undesired compounds or organic material found in Active Pharmaceutical Ingredients (APIs). Impurity are some things that's impure or makes something else impure. Even in minute amounts, the presence of those undesirable compounds might affect the efficacy and safety of medicinal medicines. Impurities don't always need to be inferior.
Cite this article:
Mansi H. Patel, Divya M. Jadav, Mitali Dalwadi, Ritika Gajre, Chainesh Shah, U. M. Upadhyay. Development of “Impurities Profiling” by using Morden Analytical Techniques: A Review. Research Journal of Pharmaceutical Dosage Forms and Technology. 2021; 13(4):329-4. doi: 10.52711/0975-4377.2021.00053
Mansi H. Patel, Divya M. Jadav, Mitali Dalwadi, Ritika Gajre, Chainesh Shah, U. M. Upadhyay. Development of “Impurities Profiling” by using Morden Analytical Techniques: A Review. Research Journal of Pharmaceutical Dosage Forms and Technology. 2021; 13(4):329-4. doi: 10.52711/0975-4377.2021.00053 Available on: https://rjpdft.com/AbstractView.aspx?PID=2021-13-4-10
1. Bondigalla Ramachandra (2016): Development of impurity profiling methods using modern analytical techniques, Critical Reviews in Analytical Chemistry,
2. Patil et al: Impurity profiling emerging trends in quality control of pharmaceuticals. International Journal of Pharmaceutical Chemistry (2015) 05 (01)
3. Shah SR, Patel MA, Naik MV, Pradhan PV and Upadhyay UM: Recent Approaches of “Impurity Profiling” in Pharmaceutical Analysis: A Review. Int J Pharm Sci Res. 3(10); 3603-3617
4. Boob DN et al., A Review on Impurities Profiling in Pharmaceutical. b American Journal of Pharm Tech Research 2018;8(3) 2249-3387
5. Warad T.A et al., Impurity profile of pharmaceuticals ingredients: A Review., Journal of pharmacy research 2016,10(7),523-533
6. Shashank rawat et al., impurity profiling: overview on impurity profiling and reporting methodologies adopted by united states and Europe. World Journal of Pharmaceutical Research 2017,14(6),206-221
7. P. Venkatesan et al., Impurity profiling: Theory and Practice. Journal of Pharmaceutical Science and Research. Vol.6(7), 2014,254-259
8. ICH Guidelines, Q3A (R2), Impurities in New Drug Substances, October 25, 2006.
9. ICH Guidelines, Q3 C (R5), Impurities in New Drug Substances, October 25, 2006.
10. ICH guidelines, Q3 D (R2), Impurities in new drug substances, October 25, 2006.
11. Bari S. Impurity profile significance in Active Pharmaceutical Ingredient; Eurasian Journal of Analytical Chemistry,2007;2:32-53
12. A Chanda, N Ramalakshmi, CN Nalini, S Mahabubi; Impurity profiling an emerging trend in Pharmaceuticals: A Review; PharmaTutor; 2015; 3(11); 29-35.
13. Nisha M, Ismail M, Ismail R, Duncan F, Maili L, Jeremy K N and John C L (1999) Impurity profiling in bulk pharmaceutical batches using 19F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR-based Diffusion Measurements. J Pharm Biomed Anal 19:511.
14. Gupta Raghav et al., A Review on the impurity profiling of Pharmaceuticals; IJDFR 2014, Vol 5(2), 53 - 83